Meeting NewsVideo
June 25, 2017
CHICAGO — Improvements in response duration and side effect profile seen in the KEYNOTE-045 trial of pembrolizumab establish this therapy…
Meeting NewsVideo
June 23, 2017
CHICAGO — Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discusses the results of a phase 3 trial…
Meeting NewsVideo
June 23, 2017
Adam M. Brufsky, MD, PhD, professor of medicine and co-director of the Comprehensive Breast Cancer Center at the University of Pittsburgh, discusses…
Meeting NewsVideo
June 23, 2017
CHICAGO — Edward S. Kim, MD, chair of solid tumor oncology and investigational therapeutics at the Levine Cancer Institute, and a HemOnc…
Meeting NewsVideo
June 22, 2017
CHICAGO — Hossein Borghaei, DO, chief of the division of thoracic medical oncology at Fox Chase Cancer Center, discusses the updated…
Meeting NewsVideo
June 22, 2017
CHICAGO — Entospletinib appeared safe for patients with relapsed or refractory lymphoplasmacytoid lymphoma, according to study results…
Meeting News
June 21, 2017
In this guest commentary,
Terence Friedlander, MD,
discusses
the
benefits associated with the addition of…
Meeting News
June 21, 2017
CHICAGO — The combination of lenvatinib and pembrolizumab conferred benefit to previously treated patients with metastatic endometrial cancer…
Meeting NewsVideo
June 21, 2017
CHICAGO — The results of the LATITUDE trial demonstrated that the addition of abiraterone acetate with prednisone to standard hormonal therapy…
Meeting NewsVideo
June 20, 2017
CHICAGO — The use of sipuleucel-T in patients with hormone-sensitive and castration-resistant prostate cancer demonstrated an increase in the…